CARVEDILOL IN PATIENTS WITH UNCONTROLLED AND RESISTANT ARTERIAL HYPERTENSION

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Management

Background:

• Resistant hypertension management requires further investigation into beta-blocker efficacy.
• Previous studies like PATHWAY-2 showed benefits of bisoprolol but did not fully address diastolic blood pressure or calcium channel blocker (CCB) intolerance.
• Understanding the role of different beta-blockers is crucial for guiding treatment in complex hypertensive patients.

Purpose of the Study:

• To evaluate the efficacy of carvedilol, a non-selective beta-blocker with alpha-1 blocking properties, in treating resistant hypertension.
• To assess carvedilol's effectiveness in patients intolerant to calcium channel blockers (CCBs).
• To compare carvedilol's efficacy when initiated in treatment-naïve patients versus when switched from another beta-blocker.

Main Methods:

• Two groups were studied: "Add Carvedilol" (beta-blocker-naïve patients with resistant hypertension on triple therapy) and "Switch to Carvedilol" (CCB-intolerant patients switched from bisoprolol to carvedilol).
• Primary endpoint: change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline.
• Secondary endpoints: correlation of blood pressure reduction with demographics and safety parameters (hypotension, bradycardia, new-onset type 2 diabetes mellitus).

Main Results:

• Significant reductions in both SBP and DBP were observed in both the "Add Carvedilol" and "Switch to Carvedilol" groups.
• Carvedilol demonstrated effectiveness in patients receiving standard triple therapy (CCB, RAAS inhibitor, diuretic) and in those intolerant to CCBs.
• The drug was well-tolerated, with no significant adverse events reported, indicating a favorable safety profile.

Conclusions:

• Carvedilol is an effective treatment option for patients with resistant hypertension.
• The study supports the use of carvedilol, particularly in patients intolerant to calcium channel blockers.
• Carvedilol provides significant blood pressure reduction with good tolerability in resistant hypertension management.